Quantcast

Latest Phenols Stories

2014-09-16 12:31:25

SAN FRANCISCO, Sept. 16, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK((TM)) (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. Opioids play an important role in chronic pain relief...

2014-09-16 08:29:45

Results Validating the Multi-Modal Mechanism of Action Would Provide the Basis for Differentiating LevoCap ER from other Pain Therapies NEW YORK, Sept. 16, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has entered into an agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in a series of animal studies for levorphanol, the active ingredient of...

2014-09-15 12:28:06

DUBLIN, Sept. 15, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 presents comprehensive data on paracetamol (acetaminophen) markets globally and regionally (Europe, Asia, North America etc.) The report includes paracetamol (acetaminophen)...

2014-09-10 08:30:33

Key Step Accomplished Signals the Initiation of Clinical Development for Potential Blockbuster d-methadone NEW YORK, Sept. 10, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCBB: RLMD) ("Relmada" or the "Company"), a clinical stage company developing novel therapies for the treatment of chronic pain, today announced that it has filed a Clinical Trial Application (CTA) with Heath Canada to conduct 2 pharmacokinetic studies with d-methadone, its NMDA receptor antagonist for...

2014-09-09 08:30:47

AT-003 Demonstrates Greater Pain Control Over Time Compared to Placebo in Client-Owned Dogs KANSAS CITY, Kan., Sept. 9, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced positive results from its pilot field study of its Bupivacaine Extended-Release Injectable Suspension (AT-003) for managing post-operative pain in...

2014-09-08 08:30:58

Studies to Investigate Ability of KP201 to Deter Abuse and Reduce Opioid-Induced Constipation CORALVILLE, Iowa, Sept. 8, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the initiation of clinical trials of KP201 designed to investigate the drug candidate's ability to deter abuse and reduce opioid-induced constipation. KP201 (benzhydrocodone hydrochloride...

2014-09-06 23:01:56

Homeostatic cannabinoid science is the focus found in new research articles from the National Institutes of Health (PubMed), with a spotlight on ultralow doses of THC protecting the brain from inflammation-induced cognitive deficits. Publius, of The Cannabis Papers: A citizen’s guide to cannabinoids (2011), provides the voice and “Yes We Can” expectations for science and our health. Chicago, IL (PRWEB) September 06, 2014 “THC has a high reputation,” opened Bryan W. Brickner,...

2014-09-04 16:27:27

STAMFORD, Conn., Sept. 4, 2014 /PRNewswire/ -- Purdue Pharma is presenting results from several studies and post-hoc analyses evaluating extended-release, single-entity hydrocodone bitartrate tablets, including the analgesic effectiveness and safety among patients transitioning from immediate-release hydrocodone combination products and the formulation's abuse-deterrent potential in recreational opioid abusers at PAINWeek national conference Sept. 2 - 6 in Las Vegas....

2014-08-31 04:21:07

Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in the ODYSSEY LONG TERM trial TARRYTOWN, New York and PARIS, Aug. 31, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia.(...

2014-08-31 04:20:55

- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial - PARIS and TARRYTOWN, N.Y., Aug. 31, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia....


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related